GI Therapeutics Announces Publication Of Real World Outcomes Data Of Impact Of Trilaciclib On Myelosuppressive Events In Patients With Extensive Stage Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
GI Therapeutics has published real-world outcomes data showing that Trilaciclib reduces single and multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events (HAEs) in patients with extensive stage small cell lung cancer. The data also showed lower cytopenia-related healthcare utilization and all-cause hospitalization among patients receiving Trilaciclib.
July 31, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive data on Trilaciclib's effectiveness could potentially boost GI Therapeutics' revenues and stock price.
The publication of positive real-world outcomes data for Trilaciclib, a product of GI Therapeutics, indicates its effectiveness in reducing HAEs in lung cancer patients. This could lead to increased demand for the drug, potentially boosting the company's revenues and, consequently, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100